Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› HER2-positive Breast Cancer
Clinical trial register · China

HER2-positive Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 18 Guangzhou 15 Shanghai 10 Hefei 7 Bengbu 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shu Wang7 Fudan University6 Sichuan Baili Pharmaceutical Co., Ltd.5 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University4 Hebei Medical University Fourth Hospital2
Site location
Beijing18 Guangzhou15 Shanghai10 Hefei7 Bengbu6
All 39 locations
Target enrolment
to

HER2-positive Breast Cancer trials in China

53 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
NCT07892274Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
DrugsDalpiciclib·Pyrotinib·Trastuzumab Rezetecan·Fulvestrant
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
226
Guangzhou
2026-11-01
Not yet open
Fudan University
Phase 2
358
Shanghai
2026-10-01
Not yet open
First Affiliated Hospital of Zhejiang University
Phase 2
80
Hangzhou
2026-09
Recruiting
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-08-10
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
20
Hangzhou
2026-06-01
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Nanjing, Shanghai, Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou
2026-05-21
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
596
Guangzhou, Chengdu
2026-04-21
Recruiting
The First Affiliated Hospital of Soochow University
Phase 2
124
Suzhou
2026-03-24
Recruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3
540
Beijing
2026-02-10
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
NCT07486089Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)
DrugEb-Dt-Car-Nk
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
NCT07510802Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
Beijing Biotech
Phase 1/2
60
Shenzhen
2026-02-02
Recruiting
T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
NCT07152782Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
DrugsNeratinib·Trastuzumab deruxtecan
Fudan University
Phase 2
202
Shanghai
2025-09-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Not yet open
Fudan University
Phase 2
288
Shanghai
2025-09-10
Recruiting
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
NCT06892093HER2-positive Breast Cancer, Diarrhea Caused by Drug, Neratinib
DrugLoperamide
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
308
Guangzhou
2025-08-07
Recruiting
Fudan University
Phase 3
2,306
Shanghai
2025-07-08
Recruiting
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
NCT07708194Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
DrugsEntinostat·Pyrotinib
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
94
Tianjin
2025-06-23
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
985
Bengbu, Hefei, Chongqing, Fuzhou, Guangzhou, Shenzhen, Liuzhou, Nanning
2025-06-05
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
1,450
Nanjing, Shanghai
2025-06-03
Recruiting
Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
NCT07358182Trastuzumab-rezetecan, HER2-low Breast Cancer, HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
300
Guangzhou
2025-06-01
Recruiting
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Recruiting
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
NCT06832904HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib
First Affiliated Hospital of Zhejiang University
Phase 2
33
Hangzhou
2024-12-03
Not yet open
Fudan University
Phase 2
242
Shanghai
2024-09
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
83
Guangzhou
2024-06-19
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
274
Guangzhou
2024-05-08
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3
964
Beijing
2024-04-30
Recruiting
Hebei Medical University Fourth Hospital
Phase 2
182
Shijiazhuang
2024-04-30
Recruiting
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3
442
Shanghai
2024-03-13
Active, closed
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
Henan Cancer Hospital
Phase 2
71
Henan
2024-01-20
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Recruiting
Hebei Medical University Fourth Hospital
Phase 4
100
Shijiazhuang
2024-01-02
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
365
Shanghai
2023-07-18
Recruiting
Peking Union Medical College Hospital
Observational
300
Beijing
2023-06-01
Recruiting
Henan Cancer Hospital
Phase 2
610
Zhengzhou
2023-05-03
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 2
188
Nanjing
2023-04-08
Recruiting
Shengjing Hospital
Phase 2
65
Shenyang
2023-03-16
Recruiting
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
NCT05760612Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab, RCB Classification 1-2
DrugTrastuzumab and Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
300
Guangzhou
2023-03-14
Recruiting
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
NCT07073755Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer, HER2-positive Breast Cancer
Hunan Cancer Hospital
Observational
200
Changsha
2023-01-01
Active, closed
Caigang Liu
Phase 2/3
136
Shenyang
2022-05-23
Active, closed
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Ma’anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Hefei, Guangzhou, Meizhou, Liuzhou, Nanning, Haikou, Baoding, Zhengzhou
2022-03-07
Recruiting
zhangjie
Observational
60
Fuzhou
2021-06-01
Recruiting
Peking University
Phase 2
104
Beijing
2020-07
Recruiting
Fudan University
Not applicable
94
Shanghai
2020-04-21
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Guangzhou, Zhanjiang, Zhengzhou, Changsha, Wuhan, Nanjing, Xuzhou, Nanchang
2019-10-02
Recruiting
Shu Wang
Observational
2,806
Beijing
2019-01-01
Recruiting
Shu Wang
Observational
2,092
Beijing
2019-01-01
Recruiting
Shu Wang
Observational
8,077
Beijing
2019-01-01
Recruiting
Shu Wang
Observational
2,916
Beijing
2019-01-01
Recruiting
Shu Wang
Observational
171
Beijing
2019-01-01
Recruiting
Shu Wang
Observational
519
Beijing
2015-01-01
Recruiting
Shu Wang
Observational
285
Beijing
2015-01-01
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/condition/her2-positive-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies listing the condition HER2-positive Breast Cancer.

How many HER2-positive Breast Cancer trials are recruiting in China?

40 of the 53 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (HER2-positive Breast Cancer), 53 studies
PhaseStudiesRecruitingShare
Phase 2151028.3%
Phase 315828.3%
Observational121222.6%
Phase 2/3437.5%
Not applicable335.7%
Phase 1/2335.7%
Phase 4111.9%

Most active sponsors

Lead sponsors with the most studies (HER2-positive Breast Cancer)
Lead sponsorStudiesRecruiting
Shu Wang77
Fudan University63
Sichuan Baili Pharmaceutical Co., Ltd.53
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University43
Beijing Biotech22
First Affiliated Hospital of Zhejiang University21
Hebei Medical University Fourth Hospital22
Henan Cancer Hospital22
Seagen, a wholly owned subsidiary of Pfizer20
Caigang Liu10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.